Discounted tickets are available now!
New York Professional Events List
2nd Strategic Partnerships for Drug Repurposing Forum
Date
Organizer
Venue
Location
Drug repurposing, repositioning, and rescue all allow pharmaceutical companies to maintain or increase the lifecycle of drugs and decrease the expense of the full research and development process. In today’s society, life science organizations not only develop strategies and methods to help find cures for diseases; they also utilize data from past clinical trials to uncover potential new indications to repurpose, reposition or rescue a drug. With more than 7,000 known diseases worldwide, drug repurposing provides an alternative route for companies to provide treatments to patients faster.
At ExL’s 2nd Strategic Partnership for Drug Repurposing Forum you will hear the latest indications for repurposing, rescuing and repositioning existing drugs to explore the newest innovations. Attendees will learn about the different resources available to them, including public-private partnerships, foundations, patient advocacy groups, universities and other funding partners. Come network and build partnerships with all stakeholders.
CONFERENCE CO-CHAIRS
|
Craig Wegner, Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, ASTRAZENECA PHARMACEUTICALS |
Bruce Bloom, President and Chief Science Officer, CURES WITHIN REACH |
FEATURED SPEAKERS
|
Zhichao Liu, Staff Fellow, NCTR, FDA |
Bobbie Austin, Program Officer, Drug Development Partnership Programs, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES, NIH |
Pankaj Agarwal, Senior Fellow, Computational Biology, GLAXOSMITHKLINE |
Raymond K. Houck, President and Chief Executive Officer, THAR PHARMACEUTICALS |
Bernadette Siddiqi, Research Programs Officer, MICHAEL J. FOX FOUNDATION |
Alex Aliper, President of European Operations, INSILICO MEDICINE |
Top Five Reasons to Attend
- Engage in case studies and panel discussions on how to excel in searching for drug repurposing opportunities and uncover new indications for existing drugs
- Cover new methods in the pipeline by using innovative strategies to discover new therapeutic uses for existing molecules
- Identify new technologies used for the evaluation of repurposed drugs
- Explore how to develop strategic partnerships between the government, universities, patient advocacy groups, foundations, and sponsors
- Understand the FDA regulations (505b) for New Drug Applications, the legal framework and intellectual property laws surrounding drug repurposing
Who Should Attend
This conference is designed for representatives from pharmaceutical, biotechnology and medical device organizations; patient organizations; and nonprofit foundations with responsibilities in the following areas:
|
|
This event is also of interest to professionals involved in:
|
|
Day One
Thursday, October 26, 2020
8:45AM – 9:00AM
Co-Chairpersons’ Opening Remarks
Bruce Bloom, President and Chief Science Officer, CURES WITHIN REACH
Craig Wegner, Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, ASTRAZENECA PHARMACEUTICALS
9:00AM – 9:45AM
Big Data and Drug Repositioning: Made for Each Other
Aris Persidis, President, BIOVISTA
9:45AM – 10:30AM
Craig Wegner, Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, ASTRAZENECA
11:00AM – 11:45AM
PANEL: Partnerships With Sponsors, Patient Advocacy, Government and Research of Drug Developments
Brian Fisher, Vice President of Operations and Corporate Partnerships, STURGE-WEBER FOUNDATION
Bobbie Austin, Program Officer, Drug Development Partnership Programs, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES, NIH
Chitra Edwin, RAC Senior Vice President of Regulatory Affairs and Compliance, SPOTLIGHT INNOVATION
Sean Evans, Director, Planning and Market Analysis, Johns Hopkins Medicine
11:45AM – 12:30PM
Heather Stone, Public Health Analyst, FDA
1:30PM – 2:15PM
Recycling the Recycling Model: Building Economic Incentives Into Generic Drug Repurposing
Bruce Bloom, President and Chief Science Officer, CURES WITHIN REACH
2:15PM – 3:00PM
Panel: Two Case Studies on Computational Strategies for Drug Repurposing
Moderator:
Bobbie Austin, Program Officer, Drug Development Partnership Programs, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES, NIH
Panelists:
David M. Aronoff, Director, Division of Infectious Diseases, Addison B. Scoville Jr. Chair in Medicine, Professor of Medicine, VANDERBILT UNIVERSITY
Bin Chen, Assistant Professor, Dept. of Pediatrics and Institute for Computational Health Sciences, UCSF
3:00PM – 3:45PM
Pharma Experiences and Challenges in Evolving New Technologies for Repurposing Drugs
Pankaj Agarwal, GSK Senior Fellow, Computational Biology, GLAXOSMITHKLINE
4:15PM – 5:00PM
Hassan Al-Ali, Ph.D., Research Assistant Professor, UNIVERSITY OF MIAMI; Chief Scientific Officer, TRUVITECH LLC
5:00PM – 5:45PM
Integrative Technology Platform to Speed Up the Process of Drug Repurposing
Stephen Wong, Chairman and Professor, Department of Systems Medicine and Bioengineering, and Chief Research Information Officer, HOUSTON METHODIST HOSPITAL
5:45PM – 5:45PM
Day Two
Friday, October 27, 2020
8:30AM – 8:45AM
Co-Chairpersons’ Recap of Day One
Bruce Bloom, President and Chief Science Officer, CURES WITHIN REACH
Craig Wegner, Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, ASTRAZENECA PHARMACEUTICALS
8:45AM – 9:30AM
Predict the Safety and Efficacy of Small Molecules Using Deep Learning Techniques
Alex Aliper, President of European Operations, INSILICO MEDICINE
9:30AM – 10:15AM
Drug Repurposing for Rare Diseases at National Center of Toxicological Research
Zhichao Liu, Staff Fellow, NCTR, FDA
10:15AM – 11:00AM
Daphna Laifenfeld, Senior Director, Personalized and Predictive Medicine, TEVA
11:30AM – 12:15PM
PANEL: How to Evaluate the Pricing and Value of a Repurposed Drug
Antoun Nabhan, Chief Financial Officer, ESTABLISHMENT LABS
12:15PM – 1:00PM
CASE STUDY: Engaging the Patient Community in Repurposed Drug Trials
Bernadette Siddiqi, Research Programs Officer, THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH
2:00PM – 2:45PM
CASE STUDY: The Development of a New Molecule of an Old Drug in a New Orphan Disease
Raymond K. Houck, President and Chief Executive Officer, THAR PHARMACEUTICALS
2:45PM – 3:15PM
CASE STUDY: Explore Development Paths and Challenges in Drug Repurposing
Neal Farber, Chief Executive Officer, NEUROHEALING PHARMACEUTICALS
3:45PM – 4:15PM
A KnowledgeBase to Aggregate and Prioritize Data on Generic Drug Repurposing for Cancer
Laura Kleiman, Executive Director, CURES WITHIN REACH FOR CANCER
4:15PM – 4:15PM